CTI BioPharma   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Seattle WA United States (1991)
Status: Acquired by Swedish Orphan Biovitrum (2023) → now Advent International (2021)

Organization Overview

First Clinical Trial
1998
NCT00004026
First Marketed Drug
2000
arsenic trioxide (trisenox)
First NDA Approval
2000
arsenic trioxide (trisenox)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cell Therapeutics | CTI BioPharma | CTI BIOPHARMA CORP | CTI Clinical Trial & Consulting Services